Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.

The reduction in body weight was continuous across the dosing period and ranged from -2.5% to -3.4% at 12 weeks and -1.2% in placebo although this did not reach statistical significance. 40 After 12 weeks the change in body weight with dapagliflozin in T2DM patients taking insulin and insulin sensitizers was -4.3 to -4.5 kg in the dapagliflozin treatment groups versus -1.9 kg with placebo ( Figure 4 ). 41 Both 24-week and 48-week studies were consistent with this effect of dapagli

also in 111,027 other papers